ALKS - Alkermes Plc
Alkermes Plc Logo

ALKS - Alkermes Plc

https://www.alkermes.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bearish
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday - Cogent Biosciences ( NASDAQ:COGT ) , Alkermes ( NASDAQ:ALKS )
Benzinga • 1 week, 5 days ago • score: -0.22
U.S. stocks were mixed, with the Dow Jones index falling over 150 points on Wednesday. Shares of Macy's, Inc. M rose sharply during Wednesday's session after the company reported second-quarter results above estimates and raised its FY2025 guidance.
Neutral
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Archrock ( NYSE:AROC ) , Alkermes ( NASDAQ:ALKS )
Benzinga • 1 week, 5 days ago • score: -0.02
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Compass Point analyst Ed Engel initiated coverage on Bullish BLSH with a Neutral rating and ...
Bearish
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Bruker ( NASDAQ:BRKR ) , Alkermes ( NASDAQ:ALKS )
Benzinga • 1 week, 5 days ago • score: -0.63
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 150 points on Wednesday. Shares of Bruker Corp BRKR fell sharply in pre-market trading after the company announced a $600 million public offering. Bruker shares tumbled 9.8% to $29.98 in the pre-market ...
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.

52W High
$36.45
52W Low
$25.56
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.49
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
14.46
Forward P/E (<15 better)
17.83
EV/EBITDA (<8 favorable)
8.88
EV/Revenue (<3 favorable)
2.66
P/S (TTM) (<3 favorable)
3.28
P/B (<3 favorable)
3.04
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
1.49%
Institutions (25–75% balanced)
104.98%
Shares Outstanding
165,078,000
Float
162,415,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
1,505,296,000
Gross Profit (TTM)
1,281,424,000
EPS (TTM)
2.07
Profit Margin (>10% good)
0.23%
Operating Margin (TTM) (higher better)
0.24%
ROE (TTM) (>15% strong)
0.24%
EPS YoY (Quarterly) (>10% good)
-0.02
Revenue YoY (Quarterly) (>8% good)
-0.02
Momentum
Bearish momentum
Value
-0.0832
Previous
0.0051
Trend
Falling
Signal Cross
No cross
As of
Sep. 11, 2025